Form 4: NeoGenomics EVP Exercises Options, Sells Shares
Insider Transaction Report
Alicia C. Olivo, EVP, GC & Business Development at NeoGenomics, exercised stock options and subsequently sold a portion of her common stock holdings under a pre-arranged 10b5-1 trading plan.
Summary
- Alicia C. Olivo, Executive Vice President, General Counsel, and Head of Business Development, acquired 8,977 shares of NeoGenomics common stock through the exercise of stock options at a price of $10.05 per share.
- On the same date, Ms. Olivo sold 20,916 shares of common stock at a price of $12.00 per share.
- These sales were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by the Reporting Person.
- Following these transactions, Ms. Olivo directly beneficially owns 31,083 shares of common stock.
- She also holds a significant number of derivative securities, including various stock options, restricted stock units (RSUs), and performance stock units (PSUs), representing potential future share ownership.
Sentiment
Score: 6
Explanation: The transaction is largely routine, involving the exercise of options and a pre-planned sale. While a sale by an insider can be seen negatively, the 10b5-1 plan mitigates this, and the executive retains a significant stake, indicating continued alignment with company performance.
Positives
- The exercise of stock options by a key executive demonstrates continued engagement and the realization of compensation benefits.
- Ms. Olivo retains a substantial beneficial ownership in the company, including 31,083 direct common shares and a large portfolio of unexercised options, RSUs, and PSUs, aligning her interests with shareholders.
Negatives
- The sale of 20,916 shares by a senior executive, even if pre-planned, reduces her direct common stock holdings.
Future Outlook
NA
Industry Context
This filing details an individual executive's stock transactions and does not provide broader industry context or trends. It is specific to the compensation and personal trading activities of a NeoGenomics executive.
Stakeholder Impact
- Minimal direct impact on shareholders as this is a routine, pre-planned insider transaction related to executive compensation.
- No direct impact on employees, customers, suppliers, or creditors from this specific filing.
Key Dates
| Date | Description |
|---|---|
| 09/30/2019 | Grant date for 1,394 stock options to Ms. Olivo, vesting ratably over four years. |
| 05/01/2020 | Grant date for 1,024 stock options to Ms. Olivo, vesting ratably over four years. |
| 05/01/2021 | Grant date for 516 stock options to Ms. Olivo, vesting ratably over four years. |
| 08/01/2021 | Grant date for 1,117 stock options to Ms. Olivo, vesting ratably over four years. |
| 05/01/2022 | Grant date for 22,222 stock options to Ms. Olivo, vesting ratably over four years. |
| 09/01/2022 | Grant date for 55,332 stock options to Ms. Olivo, vesting ratably over four years. |
| 05/11/2023 | Grant date for 36,508 stock options, 19,508 restricted stock units, and 19,508 performance stock units to Ms. Olivo, vesting ratably over three years. |
| 02/23/2024 | Grant date for 42,344 stock options, 25,330 performance stock units, and 25,329 restricted stock units to Ms. Olivo, vesting ratably over three years. |
| 02/21/2025 | Grant date for 107,450 premium-price stock options and 63,238 restricted stock units to Ms. Olivo, vesting ratably over three years. |
| 11/25/2025 | Date of stock option exercise and common stock sale by Ms. Olivo. |
| 01/13/2026 | Vesting date for 59,382 Restricted Stock Units. |
| 05/11/2026 | Vesting/measurement date for 19,508 Performance Stock Units. |
| 09/30/2026 | Expiration date for 1,046 stock options granted on 09/30/2019. |
| 02/23/2027 | Vesting/measurement date for 25,330 Performance Stock Units. |
| 05/01/2027 | Expiration date for 1,024 stock options granted on 05/01/2020. |
| 05/01/2028 | Expiration date for 516 stock options granted on 05/01/2021. |
| 08/01/2028 | Expiration date for 1,117 stock options granted on 08/01/2021. |
| 05/01/2029 | Expiration date for 22,222 stock options granted on 05/01/2022. |
| 09/01/2029 | Expiration date for 8,977 stock options granted on 09/01/2022. |
| 05/11/2030 | Expiration date for 36,508 stock options granted on 05/11/2023. |
| 02/23/2034 | Expiration date for 42,344 stock options granted on 02/23/2024. |
| 02/21/2035 | Expiration date for 107,450 stock options granted on 02/21/2025. |
Recommendation
holdThis Form 4 filing details a routine insider transaction involving the exercise of stock options and a subsequent sale of shares under a pre-arranged 10b5-1 trading plan. Such transactions are typically part of an executive's long-term compensation strategy and do not usually signal a change in the company's fundamental outlook or performance. The executive retains a substantial beneficial ownership, indicating continued alignment with shareholder interests. Therefore, this filing alone does not warrant a change in investment recommendation; a 'hold' stance is appropriate, pending further fundamental analysis of the company's operations and financial results.
Keywords
NeoGenomics, NEO, Alicia Olivo, Insider Trading, Form 4, Stock Options, Restricted Stock Units, Performance Stock Units, 10b5-1 Plan, Executive Compensation, Share Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.